【摘要】 目的 分析老年活动期类风湿关节炎患者采用艾拉莫德片联合雷公藤多苷片方案治疗的临床疗效。方法 老年活动期类风湿关节炎患者100例,按奇偶数分为对照组与观察组,每组50例。对照组使用艾拉莫德片方案治疗,观察组采取艾拉莫德片联合雷公藤多苷片方案治疗。比较两组中医证候积分、炎症因子、病情改善情况、不良反应发生情况及疾病复发率。结果 治疗后,观察组关节肿胀、晨僵、疲劳无力、盗汗积分分别为(1.16±0.32)、(0.86±0.15)、(0.73±0.21)、(0.82±0.19)分,低于对照组的(2.12±0.26)、(1.86±0.34)、(1.22±0.24)、(1.18±0.27)分(P<0.05)。治疗后,观察组肿瘤坏死因子-α、C反应蛋白、红细胞沉降率、白细胞介素-6低于对照组(P<0.05)。治疗后,观察组疼痛、僵硬、身体功能评分分别为(4.17±0.31)、(1.83±0.15)、(18.73±2.57)分,低于对照组的(8.35±0.28)、(3.04±0.21)、(29.15±3.63)分(P<0.05)。两组不良反应发生率比较无差异(P>0.05)。跟踪随访6个月内,观察组疾病复发率2.00%低于对照组的14.00%(P<0.05)。结论 老年活动期类风湿关节炎患者采用艾拉莫德片联合雷公藤多苷片方案治疗,在使患者病情、病症等得到有效改善的同时,患者用药安全性及疾病治疗远期疗效均良好。更多还原

【Abstract】 Objective To analyze the clinical effectiveness of elderly patients with active rheumatoid arthritis using iguratimod tablets combined with tripterygium glycosides tablets. Methods 100 elderly patients with active rheumatoid arthritis were allocated to two groups: the reference group and the observation group by means of odd-even number method, each comprising 50 patients. The reference group used the regimen of iguratimod tablets; the observation group adopted the regimen of iguratimod tablets plus tripterygium glycosides tablets. The two patient groups were compared for TCM syndrome scores, inflammatory marker, improvement of the condition, adverse reactions, and disease recurrence rates. Results Post-treatment, the scores for joint swelling, morning stiffness, fatigue and weakness, and night sweats in the observation group were(1.16±0.32),(0.86±0.15),(0.73±0.21), and(0.82±0.19) points, which were lower than those of the reference group [(2.12±0.26),(1.86±0.34),(1.22±0.24), and(1.18±0.27) points](P<0.05). Post-treatment, the observation group exhibited lower levels of tumor necrosis factor-α, C-reactive protein, erythrocyte sedimentation rate, and interleukin-6 compared to the reference group(P<0.05). Post-treatment, the pain, stiffness, and physical function scores in the observation group were(4.17±0.31),(1.83±0.15), and(18.73±2.57) points, all lower than those of the reference group [(8.35±0.28),(3.04±0.21), and(29.15±3.63) points](P<0.05). Comparison of rate of adverse reactions between the two groups showed no difference(P>0.05). During the 6-month follow-up period, the observation group showed reduced disease recurrence rate(2.00%) than the reference group(14.00%)(P<0.05). Conclusion In elderly patients with active rheumatoid arthritis, treatment with a combination of iguratimod tablets and tripterygium glycosides tablets has effectively improved disease progression and symptoms, while also demonstrating good drug safety and long-term therapeutic efficacy.更多还原